Study finds link between GMOs and current health care crisis.
These following observations are based on the mathematical matrix of BioAcoustic Biology developed over the last 20 years by the Sound Health Research Center located in Albany, Ohio, USA. The system allows for the evaluation of any aspect of the body and biochemistry in terms of numeric values, a.k.a. Frequency Equivalents.
Research efforts at the Institute of BioAcoustic Biology often evaluate clients who exhibit gluten sensitivity along with myriad associated diseases. In light of this new information, it was imperative that this data be added to their analytical software databases. The three proteins identified by the Anderson study were translated into BioAcoustic biofrequency biomarkers.* The resulting numeric matrix showed that the metabolic pathways influenced by these proteins were linked to nearly all systems of the human body; causing immune distortion, acute cellular inflammation, and disruptions in cell communication.
The original article listed three proteins, w-5 gliadin (wheat), g-3 hordein (barley), and g secalins (rye) that were implicated in the production of specific antigliadin antibody reactions. These proteins, which have been proven to be responsible for allergic reactions, are associated with grain glutens from which they are derived.
Patent records indicated the grains involved are genetically modified organisms (GMOs) developed and patented by a multinational agricultural biotech conglomerate. This would confirm that the present-day epidemic of gluten sensitivities/allergies stems from laboratory-created grains.
These gluten-distorted, allergy-causing, "engineered" grains are being used to create foods that we eat every day: bread, cereals, crackers, pastry, seasonings, even some packaged chip products contain wheat. BioAcoustic Biology matrix correlations revealed how thoroughly our health is being negatively influenced by these GMOs.
Further investigation revealed that the engineered genes contained two substitutions that distorted the way the body processes two sulfur-rich amino acids: proline and glutamine. Disturbances in these amino acid substitutions result in the impedance of the methylation of these two essential nutrients.
BioAcoustically speaking, glutamine distortions seem to be the most destructive. The enzyme required to utilize glutamine is glutamate decarboxylase (GAD; a.k.a. glutamic acid decarboxylase). Glutamate is a key molecule in cellular metabolism and the most abundant excitatory neurotransmitter in a vertebrate nervous system.
In mammals, GAD exists in two isoforms encoded by two different genes--GAD1 and GAD2. GAD1 and GAD2 are expressed in the brain where GABA is used as a neurotransmitter; GAD2 is also expressed in the pancreas.
This led to an evaluation of the GAD genomes and what happens when these genes are activated:
GAD is an enzyme that catalyzes the decarboxylation (part of the process of breaking down for use by the body) of glutamate to GABA (gamma aminobutyric acid) and CO2.
GABA is a natural tranquilizer and an important inhibitory neurotransmitter that helps regulate neuron activity and the body's nanosensors. Starting with the GAD enzyme response and moving toward GABA in conjunction with the active form of B6 (PLP), the nanotransmitters of the body are created and regulated. The movement of electrical energy and hence magnetic potential within the body are controlled by these nanotransmitters.
GAD uses PLP (pyridoxal 50-phosphate) as a cofactor. PLP was granted a patent by the US government patent office to the Canadian company Medicure. PLP is now under the control of the pharmaceutical industry, and its lack is often associated with blood clotting distortions, migraines, neural disorders, and seizures.
Nanotransmitters produced in conjunction with GAD metabolism show direct associations with a multitude of diseases: diabetes, autism, arthritis, Parkinson's, ALS, multiple sclerosis, joint pain and deterioration, auditory disorders, celiac disease, Crohn's, irritable bowel syndrome, diverticulitis, schizophrenia, bipolar and anxiety disorders, aspartame sensitivity, MSG reactions, lupus, fibromyalgia, depression, seizures, brain signaling, the use of calcitonin (cancer related), histidine function (seasonal allergies), cellular inflammation, and vaccination reactions.
Of particular importance is GAD's involvement with cancer via calcitonin, a 32-amino acid peptide/hormone that participates in calcium and phosphorus metabolism. BioAcoustically speaking, calcitonin is a major player in the role of how the body handles any cancer threat.
Parkinson's is an incurable, debilitating disease that also shows GAD involvement. The activity of GAD was studied in autopsy brain samples from six Parkinson's patients and 13 controls. It was significantly reduced in brain samples of patients with Parkinson's disease, being about 50% of that in controls. Moreover, levodopa treatment showed a tendency to increase the activity of GAD. The results suggest the involvement of GABA neurons in Parkinson's disease.
A search of the GAD literature stated that acetylcholine, [gamma]-aminobutyric acid, dopamine, calcitonin gene-related peptides, choline acetyl-transferase, and enkephalins are involved with the metabolism of GAD. It would be important to include these biochemicals when testing subjects for GAD presence and methylation.
Glutamate is the same Frequency Equivalent * as aspartame and is part of MSG (monosodium glutamate). James Oschman, in his publication Energy Medicine, states that cells emit frequency-based signals as a request for needed biochemicals to gather at the site where they are needed. Since glutamate and aspartame are the same frequency, this may explain why aspartame has been implicated in so many muscle and joint disorders.
MSG is also used as a stabilizer in some vaccines. This could account for the reported increase in autism-associated vaccination damage.
"This may be one of the decade's most important 'connections' between food and genetics. By showing the frequency relationships among substances normally found in healthy people, you have confirmed that the potential for GMO harm is very real," states health freedom advocate Ralph Fucetola, JD.
Sharry Edwards, the recognized pioneer of this emerging technology, states: "I expect this information will be the impetus that opens the world to the potential of BioAcoustic Biology and the hope of allowing access to Self Health care via easy-to-use software; even after the appearance of a disease process."
From the original Science News article:
Three protein fragments are looking like the guilty parties in celiac disease, an intestinal ailment that affects as many as one in 133 people in the United States. These partial proteins, or peptides, are the part of gluten in wheat, rye and barley that triggers the immune systems of celiac patients, damaging the small intestine. An Australian research team reports the new findings in the July 21 Science Translational Medicine. ... This is an impressive and very comprehensive study," says immunologist Ludvig Sollid of the University of Oslo. "The authors find that most celiac patients make a response to these three gluten peptides."
Questions: Are GMO producers aware of the damage to health that is being caused? Shouldn't those with cell signaling issues be warned about ingesting these glutens? Why are GMO producers and the US government boldly attempting to prevent package warnings that would notify people that they were eating GMO products? Is it greed, ignorance, or a misguided attempt to improve our food supply that is in fact poisoning our food, our population, and our genetic pool? Is this assault on our food supply intentionally creating a future that will keep us ill and medication dependent?
For further information about this topic, or to schedule an interview with Sharry Edwards, please call 740-698-9119 (Monday-Friday, EST) or write to email@example.com.
Adams J. Frequency of autoantibodies in celiac disease [Web article]. Celiac.com. Jan. 29, 2010. http://www.celiac.com/article/2.2001/1/Frequency-of-Autoantibodies-in-Celiac-Disease/Page1.html.
Al-Salam S, Hameed R, Parvez HS, Adeghate E. Diabetes mellitus decreases the expression of calcitonin-gene related peptide, gamma-amino butyric acid and glutamic acid decarboxylase in human pancreatic islet cells. Neuro Endocrinol Lett. 2009;30(4): 506-510.
Barova H, Perusicova J, Hill M, Sterzl I, Vondra K, Masek Z. Anti-GAD-positive patients with type 1 diabetes mellitus have higher prevalence of autoimmune thyroiditis than anti-GAD-negative patients with type 1 and type 2 diabetes mellitus. Physiol Res. 2004;53(3)279-286.
Blaylock RL. The connection between MS and aspartame [online article]. Truth In Labeling. June 7, 2004. http://www.truthinlabeling.org/Blaylock-Aspartame And Multiple Sclerosis-Neurosurgeon%27sWarning.html. Accessed 26 Sept 2010.
Fasano A. Celiac disease insights: clues to solving autoimmunity. Sci Am. August 2009. Epub 25 Oct 2010. Available at: http://www.scientificamerican.com/article.cfm?id=celiac-disease-insights.
Glutamic acid [Web page]. Absolute Astronomy. http://www.absoluteastronomy.com/topics/Glutamic_acid.
Glutamate metabolism [online document]. Listing Pathways. 26 Sept 2010. <http://pathman.smpdb.ca/pathways/SMP00072.
Hettema JM, An SS, Neale MC, et al. Association between glutamic acid decarboxylase genes and anxiety disorders, major depression, and neuroticism. Mol Psychiatry. 2006 Aug; 11 (8): 752-762. Epub 2006 May 23.
Hirota JA, Budelsky A, Smith D, et al. The role of interleukin-4R[alpha] in the induction of glutamic acid decarboxylase in airway epithelium following acute house dust mite exposure. Clin Exp Allergy. May 2010;40(5):820-830.
Humphries P, Pretorius E, Naude H. Direct and indirect cellular effects of aspartame on the brain. Eur J Clin Nutr. 2008 Apr; 62(4): 451-462. Epub 2007 Aug.
Ludvigsson J, for Linkoping Diabetes Immune Intervention Study Group. The role of immunomodulation therapy in autoimmune diabetes. J Diabetes Sci Technol. 2009 March; 3(2): 320-330.
McGeer PL, McGeer EG, Wada JA. Glutamic acid decarboxylase in Parkinson's disease and epilepsy. Neurology. 1971 Oct; 21(10): 1000-1007.
Petri S, Kollewe K, Grothe C, et al. GABA A-receptor mRNA expression in the profrontal and temporal cortex of ALS patients. J Neurol Sci. 1 December 2006;250(1):124-132. S.
Rakocevic G, Raju R, Dalakas MC Anti-glutamic acid decarboxylase antibodies in the serum and cerebrospinal fluid of patients with stiff-person syndrome. Arch Neurol. 2004;61:902-904.
Rinne UK, Laaksonen H, Riekkinen P, Sonninen V. Brain glutamic acid decarboxylase activity in parkinson's disease. Eur Neurol 1974;12:13-19. doi: 10.1159/000114599.
Sinclair M, Migraine prevention by targeting glutamate receptors? BioMedicine. April 28, 2009. Epub 22 Sept 2010. Available at: http://www.bio-medicine.org/medicine-news-1/Migraine-prevention-by-targeting-glutamate-receptors-3F-43945-1.
Taylor-Gjevre? RM, Gjevre JA. Anti-glutamic acid decarboxylase antibodies in a patient with systemic lupus erythematosus and fibromyalgia symptoms. Lupus. 2005;14(6):486-488.
Tilz GP, Dausset J, Wiltgen M. The diabetic antigen glutamic acid decarboxylase (GAD 65) in the human peripheral blood. Int Arch Allergy Immunol. 2010; 152(2).
Tornblom H, Lang B, Clover L, Knowles CH, Vincent A, Lindberg G. Autoantibodies in patients with gut motility disorders and enteric neuropathy. Scand J Castroenterol. 2007 Nov; 42(11): 1289-1293.
Westall FC, Hawkins A, Ellison GW, Myers LW. Abnormal glutamic acid metabolism in multiple sclerosis. J Neurol Sci. September 1980;47(3):353-364.
van Deutekom AW, Nurmohamed MT, Peters MJ, et al. Methotrexate and its effect on the anti-GAD titre in two patients with rheumatoid arthritis and diabetes mellitus. Ann Rheum Dis. 2008 Jul;67(7):1051-1052.
Vanderheiden BS. Possible implication of an inosinetriphosphate metabolic error and glutamic acid decarboxylase in paranoid schizophrenia. Biochem Med. February 1979;21(1):22-32.
Verrotti A, Greco R, Altobelli E, Latini G, Morgese G, Chiarelli F. Anticardiolipin, glutamic acid decarboxylase, and antinuclear antibodies in epileptic-patients. Clin Exp Med. 3(1):32-36. doi:10.1007/s102380300013.
Yip J, Soghomonian JJ, Blatt GJ. Decreased GAD67 mRNA levels in cerebellar Purkinje cells in autism: pathophysiological implications. Acta Neuropathol. 2007 May;113(5):559-568. Epub 2007 Jan 18.
Contact: Sharry Edwards, MEd
Institute of BioAcoustic Biology and Sound Health
* All issues expressed in terms of Frequency Equivalent (a "term of use" for BioAcoustic Biology), a numeric representation of a person, place, thing or emotion.
|Printer friendly Cite/link Email Feedback|
|Title Annotation:||genetically modified organisms|
|Date:||Apr 1, 2011|
|Previous Article:||Drug-free solutions to learning disabilities.|
|Next Article:||Hansel and Gretel had it easy--no high-fructose corn syrup.|